Clinical Trial Search

Primary: Safety of Intravitreal Aflibercept Injection — 0; 0 adverse events

Primary: Mean Percentage of Cocaine-positive Urines Over Course of 12 Week Treatment in Subgroup Achieving Abstinence at Baseline — 31; 28; 47; 35 Mean % of cocaine-positive urines

Primary: Overall Response Rate — 92 percentage of patients

Primary: Maximum Tolerated Dose of Tandutinib Defined by Dose Limiting Toxicities (Phase 1) — 600 mg BID

Primary: Everolimus Maximum Tolerated Dose (MTD) [Phase I] — 10 mg daily for 4 weeks of a 4 week cycle

Primary: Percentage of Participants Achieving 75 Percent Reduction From Baseline Psoriasis Area and Severity Index (PASI) Score (PASI75 Response) at Week 12 — 8.7; 9.5; 0; 5.3…

Primary: Abstinence (Week 1 - 12) — 27; 14; 38; 13 Participants

Primary: Number of Participants With Induced Peanut Desensitization at 12 Months — 9; 7 Participants

Primary: Complete Response — 3 participants

Primary: Percent Change From Baseline in Body Weight at 6 Months — 10.2; 12.7 percentage change

Primary: Objective Response Rate According to the International Response Criteria for DLBCL (Cheson 2007) — 0 objective response

Primary: Trails Making Test Part B (Executive Function) — 69.57; 81.59; 62.53; 69.25 time to completion (seconds)

Primary: Objective Tumor Response Rate — 44 percentage of participants

Primary: FLACC Pain Score Greater Than or Equal to 4 — 58; 69 Participants

Primary: Number of Participants With Dose Limiting Toxicity (DLT) - MBC and LABC Feasibility Population — 2; 1; 0; 1 participants